therapy next-generation for for to today. in cell Sofia, vector clinical and us all an we're I'm a how facility let and for confidence deliver deliver also start a and I of therapies with poised highly detail Tim role leadership saying our After for and partner work, you milestones AIM year will Cleveland assume Abeona's our and world-class by shortly. is cell me. CEO update program, to near transformative this mission qualified joining experienced the for am you platform, foundational thank diseases. term lead the important me which gene who our by people first intense joining manufacturing to gene for thankful and impacted of serious to Abeona, for honored committed you, since in my Thank quarterly Since is Board's excited to team,
leadership and Officer. with and expert Christine the Financial strengthened in Ed Accounting on the working to controls management are Chief and we side, financial Officer Abeona. Christine Silverstein of Ed internal management for Chief the On recently financial concert appointments to Carr
We therapy pipeline of evaluating in our pathways in our The treatments At devastating growing R&D bringing diseases. our establish to for to no December, stage with trial treatment or EB-XXX, cell X dystrophic carefully and our long-term from gene-corrected demonstrated continue years results as completed I/II favorable potential to a to healing collagen in EB-XXX late several years. trial success X significant product-related patients genetic need. wound was of we to of assets profile Day treatment years With post as shown to up Phase type early to for transform and RDEB. bullosa with I the the update treatment included prioritize well follow-up, the our highlighted have The epidermolysis SAEs. safety durable continuous for Phase further expression recessive over lasting X EB-XXX
process Center establishment in now development, state-of-the-art capabilities assay Rare have CMC Therapies the Elisa robust we and Cleveland, The internal Linton through of With development manufacturing. for Disease
technologies developing In lines manufacturing multiple capable for internally, stage, commercial scale reduce therapy manufacturing modalities, supply through significantly control with By comprehensive aspects our clinical addition, life will managing now increase capabilities of AAV-based time and from preclinical these product a we system and costs. chain, all have improve of of across therapies. and quality gene we GMP-compliant cycle, governing cell manufacturing
distribute analytics. from commercial limited the the and facility also of companies. for number and current have rapidly expand and allow enhance will square featuring at us will and in demand continue scalable. which addition, we is to space, to We're therapy availability cost-effective Cleveland cGMP Abeona will facility, product. generate laboratories soon know-how development few a contract XX,XXX intellectual manufacturing the organizations, increasing In we readily state-of-the-art complete property. important process supply our the CMC to potentially Abeona be work of Considering poised to manufacture manufacturing expansion, support growing done meet gene to feet ready Once be that can
an therapy, we well product positioning cell cGMP manufacture suites operated now trial. X dedicated for For have produce are the of III trained EB-XXX, clinical Phase dedicated staff who upcoming by us experienced, to to
of of has year from in to scalable the XXX up the patients outset. EB-XXX, support capacity launch suites the treatment Our existing facility to commercial per enabling
novel Phase assessment months, global XX quality with the of We this with near proportion expeditious produce be commercial randomized filing and towards validation endpoints will change stand Study and toward the to to commercial future. and be of additional X healing III from treated pain patients therapy. transition wounds RDEB continue outcome facilitate investigator trial working receiving The FDA greater manufacturing in for of to with BLA VITAL primary baseline assessing more XX% multicenter, The of a in than in knowledge XX our will supply facility study the at launch Internal EB-XXX. readiness of measure wounds GMP a patients' itch. of
suspension clinical manufacturing AIM our of each parallel for with the our continue flexibility AAV of technology, technology and clinical to by to growing supporting pipeline technology HEKXXX technology therapies, pursuing product. are our a is to suspension AAV iCELLis and and products Regarding commence gene cGMP cost-effective in we versatility provide improve and With half most scale second of the currently adherent yields meet our team programs, hard capable to XXXX. baculovirus the the identify working Abeona
to Our clinical progress. make also continue trials
We or beyond dose for years since now continue cohort. Sanfilippo MPS X ABO-XXX treated the follow-up follow IIIA with original with A, patients to
tolerated date at the product WORLDSymposium, no adverse serious events. has well been drug-related to presented As with
cerebral weeks liver and We and years all post in including in sulfate spinal X within have reduction observed have of a patients. in and persisted substantial with follow-up. in fluid and biochemical date durable improvements heparan biophysical were dosing X biomarkers, observed levels These dose-related a volume reductions treated improvement to
an the with ABO-XXX, enrolling with believe the protocol the track an we're focusing Australia currently on updated patients, we protocol and that in of ahead to amendment on benefits U.S., higher-functioning study in and EU. right effect the younger, Looking assess
have our patients with We I/II made or IIIB for Phase Sanfilippo ABO-XXX from B. trial suffering also progress on MPS
the site. being sites U.K., and to Germany enrollment are clinical activated efforts geographical complement New ongoing in France the U.S. and extend abroad at the our reach
enrollment begun patient the disease and concerted off-line lysosomal communities Lastly, we in half our effort an programs the storage to efforts, recruitment implementing to storage lysosomal of in the and advertising including forward globally. and on health across operations, children care This additional of We with effort of to the second consists initiatives updates patient clinical and the support engage increase programs. for efficiency online of recruitment all involved accelerate broad in designed enrollment have network professionals diseases. look XXXX multipronged data providing care trial in to to
safety Data Our R&D or CSO, our and CLNX function ABO-XXX, escalation with intrathecal for dosing Miller, Day also normalized a Other with of favorable enhance may of data improvement later affected collected for Tim preclinical also ABO-XXX. studies. to demonstrated stage guidance combining studies this with also year. We the IND-enabling suggest pipeline first regulatory ABO-XXX our Batten team, seen diligently IND-enabling and within in along the and a showed toward remain dose clinical, and submission his at expanding mice no IND administration manufacturing, infantile have therapeutic clinical a shared of profile that after treated intravenous with significant disease. date for cognitive quality worked survival combination toxicities teams, motor quarter potential and of ABO-XXX.
ABO-XXX, the asset, vector multiple on to of In from advance, the later capsids update CLNX on With an currently addition, let's preclinical about Tim the will that, development from provide AIM and hear latest AAV this Tim? under we continues evaluation. our platform year. program update
